Income Statement
ACTUATE THERAPEUTICS, INC.
ACTU
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
- | - |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
- | - |
|
Operating Expenses
|
22.50 | 25.16 |
|
Research & Development
|
10.29 | 18.68 |
|
Selling, General & Administrative
|
12.20 | 6.48 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-22.50 | -25.16 |
|
Non-Operating Income
|
0.27 | -2.12 |
|
Interest Income
|
0.29 | 0.22 |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
- | - |
|
Income Before Tax
|
- | - |
|
Income Tax Expense
|
- | - |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-22.23 | -27.29 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-22.50 | -25.16 |
|
Earnings Per Share (Basic)
|
-1.06 | -3.26 |
|
Diluted EPS
|
-1.06 | -3.26 |
|
Weighted Average Shares
|
21.02 | 8.37 |
|
Diluted Weighted Avg Shares
|
21.02 | 8.37 |
|
Comprehensive Income
|
- | - |